← Human Trials & Peer-Reviewed Studies
Recombinant growth hormone improves growth and adult height in patients with maternal inactivating GNAS mutations.
Plain-language guide to PMID 37440712 (2023): multicenter observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 190 patients.
Key Facts
- PMID
- 37440712
- Journal
- European journal of endocrinology
- Year
- 2023
- Study type
- Observational Study
- Authors
- Ertl DA et al. (15 authors)
- DOI
- 10.1093/ejendo/lvad085
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.
Their multicenter, retrospective, observational study describes growth in patients treated with rhGH in comparison with untreated iPPSD2/PHP1A controls.
Why It Was Studied
Maternal inactivating GNAS mutations lead to pseudohypoparathyroidism 1A (PHP1A), newly classified as inactivating parathyroid hormone (PTH)/PTHrP-signaling disorder type 2 of maternal inheritance (iPPSD2).
Patients present with resistance to PTH and other hormones, subcutaneous ossifications, brachydactyly, short stature, and early-onset obesity.
Who Took Part
The study group was 190 patients.
By PubMed's age tags, the people studied were adults.
The researchers included 190 patients, of whom 26 received rhGH.
Height, weight, body mass index at various time points, and adult height were documented.
How the Study Was Run
In design terms this was a multicenter study.
Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.
The researchers analyzed the effect of rhGH on adult height by using linear mixed models.
What Was Measured
Topics PubMed links to this paper include Growth Hormone, Human Growth Hormone, Pseudohypoparathyroidism, Dwarfism, Pituitary, Hypopituitarism, Mutation and Body Height.
Author keywords: iPPSD, pediatric, recombinant human growth hormone and short stature.
What This Means in Plain Language
The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 190 patients.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (European journal of endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.